Hampel, C., Gillitzer, R., Pahernik, S., Melchior, S. Hahn, A., Radkova, L., Achiemere, G., Klement, V., Alpini, D., and Strouhal, J. Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine. Gulyas, B., Halldin, C., Sovago, J., Sandell, J., Cselenyi, Z., Vas, A., Kiss, B., Karpati, E., and Farde, L. PET studies on the brain uptake and regional distribution of vinpocetine in human subjects. Gulyas, B., Halldin, C., Sandell, J., Karlsson, P., Sovago, J., Karpati, E., Kiss, B., Vas, A., Cselenyi, Z., and Farde, L. Gulyas, B., Halldin, C., Karlsson, P., Chou, Y. Gulyas, B., Bonoczk, P., Vas, A., Csiba, L., Bereczki, D., Boros, I., Szakall, S., Balkay, L., Emri, M., Fekete, I., Galuska, L., Kerenyi, L., Lehel, S., Marian, T., Molnar, T., Varga, J., and Tron, L. Vinpocetine pharmacokinetics in elderly subjects. Grandt, R., Beitinger, H., Schaltenbrand, R., and Braun, W. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Therapeutic efficacy of vincamine in dementia. Senile dementia: early detection 1986 580-585.įischhof, P. Long term study concerning tolerance and efficacy of vinpocetine in elderly patients suffering from a mild to moderate organic psychosyndrome. HUNGARY ARZNEIMITTEL FORSCH 1976 26(10A):1956-1962.įenzl, E., Apecechea, M., Schaltenbr, R., and Fridel, R. Study on the vasodilator effects of ethyl apovincaminate in neurosurgical patients. Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. View abstract.įeher, G., Koltai, K., Kesmarky, G., Horvath, B., Toth, K., Komoly, S., and Szapary, L. Open-labeled phase III clinical trials with vinpocetine in Japan. Comparative study of the clinical effects of vincamine + glycerol versus glycerol + placebo in the acute phase of stroke. J., Jocquet, P., Jacquy, J., and Henriet, M. Cerebrovascular Diseases 1998 8:102.ĭany, F., Merle, L., Goudoud, J. Transcranial doppler and PET observations on chronic stroke patients after two weeks iv vinpocetine therapy. View abstract.Ĭsiba, L., Kerenyi, L., Fekete, I., Tron, L., Galuska, L., and Gulyas, B. Chinese Journal of New Drugs 2008 17:405-408.Ĭervenka, F. In vivo and in vitro evaluation of push-pull osmotic pump-controlled release tablet of vinpocetine using numerical deconvolution technique. L., Wang, J., Liu, Y., Wang, Y., and Pan, W. Preliminary report on the use of ethyl apovincaminate in affections of the eyeground. View abstract.īrooser, G., Anda, L., and Doman, J. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study.
Human Psychopharmacology: Clinical & Experimental 1989 4(2):103-111.īonoczk, P., Panczel, G., and Nagy, Z.
Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Evidence to suggest that the phosphodiesterase 4 isoenzyme is present and involved in the proliferation of umbilical cord blood mononuclear cells. Production and examination of products of vinpocetine basis and \g/-cyclodextrin content. View abstract.īagoly, E., Feher, G., and Szapary, L. Comparative neuroprotective effects of pentobarbital, vinpocetine, flunarizine and ifenprodil on ischemic neuronal damage in the gerbil hippocampus. View abstract.Īraki, T., Kogure, K., and Nishioka, K.
0 kommentar(er)
